Unknown

Dataset Information

A phase 2, randomized, placebo-controlled, dose-ranging study of the calcium-sensing receptor antagonist MK-5442 in the treatment of postmenopausal women with osteoporosis.


ABSTRACT:

Context

MK-5442 is an orally bioavailable calcium-sensing receptor antagonist that is hypothesized to stimulate bone formation by stimulating endogenous secretion of a pulse of PTH. Earlier clinical and preclinical studies demonstrated increased bone mineral density (BMD) after treatment.

Objective

Our objective was to identify a dose of MK-5442 that produces osteoanabolic effects without excessive hypercalcemia.

Design and setting

This was a randomized, double-blind, placebo-controlled, parallel-group trial of private or institutional practice.

Participants and intervention

In total, 383 postmenopausal women with osteoporosis were administered daily oral MK-5442 (2.5, 5, 7.5, 10, or 15 mg) or placebo.

Main outcome measures

Serum PTH and calcium, bone tu

SUBMITTER: Halse J 

PROVIDER: S-EPMC5393499 | biostudies-literature | 2014 Nov

REPOSITORIES: biostudies-literature